(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Chronic Hepatitis B Virus Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.
The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:
- Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years.
- Chronic Hepatitis B Virus companies working in the treatment market are Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., and others, are developing therapies for the Chronic Hepatitis B Virus treatment
- Emerging Chronic Hepatitis B Virus therapies such as – PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, DA 2802, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.
- In January 2022, In a second Phase 2a/2b clinical research examining VBI-2601 (BRII-179), an immunotherapeutic candidate that targets chronic hepatitis B virus (HBV), VBI Vaccines reported that the first patient had received a dose
- In March 2021, In a Roche-sponsored Phase II combo trial for the treatment of chronic hepatitis B virus (HBV) infection, Dicerna Pharmaceuticals reported that Roche had started RG6346. The efficacy and safety of RG6346 in combination with numerous additional medicines with various modes of action will be assessed in the Phase II platform trial. Dicerna received a $25 million milestone payment in conjunction with the start of the Phase II combination trial with RG6346
- In October 2021, The clinical collaboration agreement between Antios Therapeutics and Assembly Biosciences will be used to test a triple combination therapy on people with chronic hepatitis B virus (HBV) infection
- In December 2021, In order to develop and market AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau, and Taiwan, Arbutus Biopharma Corporation and Qilu Pharmaceutical made their partnership and exclusive licencing agreement public.A $40 million upfront payment and up to $245 million in development, regulatory, and sales milestone payments were made by Qilu to Arbutus as per the terms of the contract. Furthermore, Qilu invested $15 million in equity in Arbutus at a cost of $4.19 a share
- In September 2020, in a multi-center, double-blind, randomised, positive control, Phase III Study, Ligand Pharmaceuticals began administering pradefovir to patients with chronic hepatitis B virus infections.
Chronic Hepatitis B Virus Overview
The “Hepadnaviridae” family of little DNA viruses includes the hepatitis B virus. It is an HBV-caused liver infection that is prevented by vaccination. Either an acute infection or a chronic infection can occur from a hepatitis B infection. It is known as a “acute infection” when a person first contracts the hepatitis B virus, and the majority of healthy individuals who contract the virus do not experience any symptoms and are able to get rid of it without any issues.
Get a Free Sample PDF Report to know more about Chronic Hepatitis B Virus Pipeline Therapeutic Assessment
Emerging Chronic Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:
- PBGENE-HBV: Precision Biosciences
- SBT8230: Silverback Therapeutics
- VIR-3434: Vir Biotechnology
- AB 729: Arbutus bio
- RG6346: Dicerna Pharmaceuticals
- RG7854: Roche
- Pradefovir: Ligand Pharmaceuticals
- DA 2802: Dong-A ST Co.
Route of Administration
Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Chronic Hepatitis B Virus Pipeline Therapeutics Assessment
- Chronic Hepatitis B Virus Assessment by Product Type
- Chronic Hepatitis B Virus By Stage and Product Type
- Chronic Hepatitis B Virus Assessment by Route of Administration
- Chronic Hepatitis B Virus By Stage and Route of Administration
- Chronic Hepatitis B Virus Assessment by Molecule Type
- Chronic Hepatitis B Virus by Stage and Molecule Type
DelveInsight’s Chronic Hepatitis B Virus Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Chronic Hepatitis B Virus product details are provided in the report. Download the Chronic Hepatitis B Virus pipeline report to learn more about the emerging Chronic Hepatitis B Virus therapies
Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:
Key companies developing therapies for Chronic Hepatitis B Virus are – Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, Yangshengtang Co., Ltd, Altimmune, Hoffmann-La Roche, Fujian Cosunter Pharmaceutical, Precision Biosciences, Beam Therapeutics, SCG Cell Therapy Pte Ltd, Silverback Therapeutics, Bluejay Therapeutics,Indaptus Therapeutics, Immunocore, and others.
Chronic Hepatitis B Virus Pipeline Analysis:
The Chronic Hepatitis B Virus pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
- Chronic Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Hepatitis B Virus drugs and therapies
Chronic Hepatitis B Virus Pipeline Market Drivers
- High prevalence of chronic HBV infection, increasing Research and development in Chronic Hepatitis B are some of the important factors that are fueling the Chronic Hepatitis B Virus Market.
Chronic Hepatitis B Virus Pipeline Market Barriers
- However, high cost of treatment, limited access to the diagnosis of hepatitis B and other factors are creating obstacles in the Chronic Hepatitis B Virus Market growth.
Scope of Chronic Hepatitis B Virus Pipeline Drug Insight
- Coverage: Global
- Key Chronic Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., and others
- Key Chronic Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, DA 2802, and others
- Chronic Hepatitis B Virus Therapeutic Assessment: Chronic Hepatitis B Virus current marketed and Chronic Hepatitis B Virus emerging therapies
- Chronic Hepatitis B Virus Market Dynamics: Chronic Hepatitis B Virus market drivers and Chronic Hepatitis B Virus market barriers
Request for Sample PDF Report for Chronic Hepatitis B Virus Pipeline Assessment and clinical trials
Table of Contents
| 1 | Chronic Hepatitis B Virus Report Introduction |
| 2 | Chronic Hepatitis B Virus Executive Summary |
| 3 | Chronic Hepatitis B Virus Overview |
| 4 | Chronic Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment |
| 5 | Chronic Hepatitis B Virus Pipeline Therapeutics |
| 6 | Chronic Hepatitis B Virus Late Stage Products (Phase II/III) |
| 7 | Chronic Hepatitis B Virus Mid Stage Products (Phase II) |
| 8 | Chronic Hepatitis B Virus Early Stage Products (Phase I) |
| 9 | Chronic Hepatitis B Virus Preclinical Stage Products |
| 10 | Chronic Hepatitis B Virus Therapeutics Assessment |
| 11 | Chronic Hepatitis B Virus Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Chronic Hepatitis B Virus Key Companies |
| 14 | Chronic Hepatitis B Virus Key Products |
| 15 | Chronic Hepatitis B Virus Unmet Needs |
| 16 | Chronic Hepatitis B Virus Market Drivers and Barriers |
| 17 | Chronic Hepatitis B Virus Future Perspectives and Conclusion |
| 18 | Chronic Hepatitis B Virus Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Latest Reports:
Vascular Graft Devices Market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028.
Vascular Stents Market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028.
Ventricular Assist Devices Market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028.
Resorbable Vascular Scaffolds Market
DelveInsight’s ‘Resorbable Vascular Scaffolds – Market Insight, Competitive Landscape and Market Forecast, 2028’ report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market
DelveInsight’s ‘Vein Illumination Devices – Market Insight, Competitive Landscape and Market Forecast, 2028’ report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Monkeypox Market
DelveInsight’s “Monkeypox Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
DelveInsight’s “Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Typhoid Market
DelveInsight’s “Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
DelveInsight’s “Zika Virus Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Related Reports by DelveInsight-
Gastric neuroendocrine tumours market | Bronchial spasms market | Wilms tumor market | Interbody cages market | Prefilled Syringes Market | Duchenne Muscular Dystrophy Market | Cardiac Amyloidosis Market | Encephalitis Market | Age-Related Macular Degeneration Market | Polycythemia Market | Myelofibrosis Market | Urolithiasis Market | Acute Coronary Syndrome Market | Lymphocytopenia Market | Minimal Residual Disease Market | Biliary Atresia Market | Surgical Site Infection Ssi Market | Thyroid Eye Disease Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Biochips Market | Neurovascular Devices Market | Idiopathic Pulmonary Fibrosis Market | 3d Cardiac Mapping System Market | Non Alcoholic Fatty Liver Disease Nafld Market | Complicated Intra-Abdominal Infections Market | Defibrillators Market | Anterior Cruciate Ligament Injuries Market | Intracranial Pressure Monitoring Devices Market | Adrenal Crisis Market | Cerebral Vein Thrombosis Market | Chemotherapy Induced Febrile Neutropenia Market | Refractory Angina Market | Ataxia Telangiectasia Market | Cardiac Insufficiency Market | Chronic Bronchitis Market | Diffuse Large B-Cell Lymphoma Market | Acrocallosal Syndrome Market | Dermal Mycosis Market | Achondroplasia Market | Opioid Induced Constipation Market | Hearing Aid Devices Market | Vertigo Market | Airway Stent Market Market | Chronic Lymphocytic Leukemia Market | Severe Hypoglycemia Market | Neuromodulation Devices Market | Cerebral Aneurysm Market | Pruritus Market | Scleroderma Market | Nsclc Market | Concussions Market Size
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187